Develops small-molecule therapies for organ fibrosis and inflammatory diseases.
Jun 2026Revenue $119M/yrExpenses $136M/yr
No trendCash runway ≈ 9.4 years from Jun 2026
Figures by year
When will Gyre Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $119M and expenses $136M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $117M | $105M | $11.5M |
| Dec 2024 | $106M | $89.6M | $16.2M |
| Dec 2023 | $113M | $181M | −$67.2M |
| Dec 2022 | $102M | $93.1M | $9.20M |
| Dec 2021 | $7.34M | $95.2M | −$87.9M |
| Dec 2020 | $20.9M | $78.3M | −$57.4M |
| Dec 2018 | $6.00K | $33.8M | −$33.8M |
| Dec 2017 | $1.02M | $22.8M | −$21.8M |
| Dec 2014 | $275K | $7.78M | −$7.51M |
| Dec 2013 | $3.63M | $13.7M | −$10.1M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.